Takara Bio Inc. (4974) Price & Analysis

Takara Bio Inc. is a global biotechnology enterprise, operating through its subsidiaries across Japan, the United States, China, other parts of Asia, Europe, and other international markets. Its operations are divided into two core segments: Bioindustry and Gene Therapy. Within its Bioindustry segment, the company develops research reagents and scientific instrumentation. It also delivers Contract Development and Manufacturing Organization (CDMO) services, supporting both academic and corporate clients in life sciences research and development. These CDMO offerings encompass contract services for developing regenerative medicine products, alongside ancillary services like quality control, safety evaluations, and cell banking. Furthermore, Takara Bio assists with genetic analysis and testing, including human genome sequencing, cancer gene analysis, and intestinal flora studies. It also provides advanced support for genetic engineering research, leveraging cutting-edge technologies and equipment for tasks like genome editing. The Gene Therapy segment focuses on the development and commercialization of a diverse portfolio of gene therapies. This includes Canerpaturev, an oncolytic virus derived from an attenuated herpes simplex virus type 1, designed to induce antitumor activity and tumor lysis through local injection. The segment is also advancing siTCR gene therapy, currently in Phase I/II clinical trials for synovial sarcoma, and CD19 chimeric antigen receptor therapy, also in Phase I/II trials for adult acute lymphoblastic leukemia. Additionally, the company supplies RetroNectin, a key component for gene therapy applications. Established in 2002, Takara Bio Inc. maintains its headquarters in Kusatsu, Japan, and operates as a subsidiary of Takara Holdings Inc.